AC Immune SA (ACIU)
NASDAQ: ACIU · Real-Time Price · USD
1.630
-0.050 (-2.98%)
At close: May 12, 2025, 4:00 PM
1.610
-0.020 (-1.23%)
After-hours: May 12, 2025, 5:48 PM EDT
AC Immune Revenue
AC Immune had revenue of 990.00K CHF in the quarter ending March 31, 2025. This brings the company's revenue in the last twelve months to 28.30M, up 91.20% year-over-year. In the year 2024, AC Immune had annual revenue of 27.31M with 84.51% growth.
Revenue (ttm)
28.30M CHF
Revenue Growth
+91.20%
P/S Ratio
5.24
Revenue / Employee
164,529 CHF
Employees
172
Market Cap
161.28M USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ACIU News
- 12 days ago - AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 5 weeks ago - AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease - GlobeNewsWire
- 6 weeks ago - AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025 - GlobeNewsWire
- 2 months ago - AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 6 months ago - AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients - Benzinga
- 10 months ago - AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024 - GlobeNewsWire
- 10 months ago - AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward - Seeking Alpha
- 10 months ago - AC Immune's ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer's Disease - GlobeNewsWire